VIRI Company Profile and Key Details

VIRI has shown weak momentum, losing -0.77% over the past week and -39.69% over the past quarter, though year-to-date performance is down -73.04%. Short-term trend indicators are bullishly aligned (SMA20 -13.91%, SMA50 -16.96%, SMA200 -53.65%). The stock’s 14-day RSI is 41.02 (neutral), while the ATR of 0.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.1% below its high and over 23.02% above its low.

Virios Therapeutics, Inc. generated EPS of -$0.23 over the past year. Five-year average earnings growth is -2.02%. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.05. Next year's EPS is expected at $27.59. Virios Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 11, 2024, missed forecasts by 20.0%. The prior quarter beat by -28.57%. Over the last six quarters, Apple has recorded several small beats. These include 14.29% in August 10, 2023.

Virios Therapeutics, Inc. (NASDAQ:VIRI) closed at $0.15 USD, gaining $0.02 (12.40%) from the previous close of $0.14. The stock is currently mid-range between its 52-week high and low $0.14 and $26.00. With a market capitalization of about $206.50 thousand, Virios Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.58). Key stats such as the average daily volume over the past year has been around 87.79 thousand shares, trading with heavier-than-usual volume. Headquartered in Alpharetta, GA, Virios Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gregory Duncan, the company employs approximately 4 people and listed since December 17, 2020. Virios Therapeutics, Inc. is a biotechnology firm in its development phase, dedicated to pioneering antiviral treatments for conditions that arise from an unusual immune response triggered by viral infections.

Virios Therapeutics, Inc. has 1.33 million shares outstanding. The public float is 1.04 million shares, elevated short interest at 1.76% of float. This equals 18.80 thousand shares. The short ratio is 0.64 days. Institutional investors hold 3.86% of the float. Insiders own 6.74%. Duncan Gregory Scott holds 57.46 thousand shares, Pridgen William has 52.04 thousand shares and Keefer David R has 5.00 thousand shares.

Virios Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading below this model’s fair value.

Virios Therapeutics, Inc. trades at a P/E ratio of 0.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.06 suggesting the stock is closer to book value. The P/FCF stands at -0.01, also above market averages.

Our AI price prediction model suggests that Virios Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -19.14%, with price expected at $3.59 by November 18, 2024, within a range of $2.24 to $4.87 3-Month Outlook: Projected rise of 9.23%, reaching $4.85 by January 30, 2025, with a range of $3.67 to $6.06. 1-Year Outlook: Projected loss of -95.5%, with price at $0.20 by November 04, 2025, within a range of $0.00 to $1.38.

Virios Therapeutics, Inc. (NASDAQ:VIRI) shares are down -73.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Virios Therapeutics, Inc. trading at a premium to the broader market with a P/E of 0.13. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $3.00, suggesting -32.43% downside. Our AI forecast model points to short-term weakness (-19.14% over two weeks), a medium-term rise (9.23% over three months), and a longer-term loss (-95.5% over one year), with expected trading ranges indicating moderate volatility.